Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate Cancer, Androgen ablation therapy
Eligibility Criteria
Inclusion Criteria: Has given written consent prior to any study-related activity being performed. A study-related activity is defined as any procedure that would not have been performed during the normal management of the patient. Has completed study FE200486 CS14 through visit 22. Exclusion Criterion: Has been withdrawn from the FE200486 CS14 study.
Sites / Locations
- Urology Centers of Alabama
- Advanced Urology Medical Center
- West Coast Clinical Research
- Western Clinical Research
- Urology Associate PC'
- South Florida Medical Research
- SW Florida Urological Associates
- Northeast Indiana Research, LLC
- Regional Urology
- Lawrenceville Urology
- The Urology Center
- State College Urologic Association
- University Urological Research Institute
- Urology San Antonio Research
- University of Vermont, Dept of Surgery
- Virginia Urology Center
- Investigational site
- Can-Med Clinical Research, Inc.
- The Male and Female Health and Research Centers
- Brantford Urology Research
- Burlington Professional Care
- The Female/Male Health Centres
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Degarelix (60 mg to 160 mg)
Degarelix (80 mg to 160 mg)
Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.